F-Prime Capital

Latchel, Inc. is a technology company that specializes in providing an online platform for maintenance coordination tailored for property managers and landlords. Founded in 2016 and based in Bellevue, Washington, Latchel offers tools to track maintenance requests and facilitate vendor selection. The platform aims to enhance operational efficiency by allowing residents to schedule maintenance and manage tasks, thereby improving response times and resident satisfaction. By streamlining maintenance processes, Latchel enables property management companies to increase their net margins while delivering better service to tenants.

Logixboard, Inc. is a Seattle-based company founded in 2016 that offers a cloud platform designed to enhance transparency and communication for freight forwarders. The platform addresses inefficiencies in the $2 trillion freight forwarding industry, where many firms rely on outdated methods such as paper, spreadsheets, and email for tracking shipments. By integrating with existing back-office applications, Logixboard's solution serves as a digital customer engagement layer, enabling freight forwarders to streamline their operations and improve customer service. The platform empowers companies to manage and control their freight operations more effectively, ultimately reducing costs and increasing efficiency in a traditionally low-tech industry.

RareCyte, Inc. is a life sciences company based in Seattle, Washington, that specializes in the development of liquid and tissue biopsy analysis platforms aimed at the detection of rare cells. Founded in 2009, RareCyte focuses on providing innovative technologies for the Life Sciences research, drug development, and diagnostic markets. The company offers a range of products, including sample preparation systems, staining kits, and automated fluorescence microscopy instruments. Its AccuCyte system is particularly notable for enabling the unbiased discovery and isolation of circulating tumor cells and circulating endothelial cells from whole blood. RareCyte's technologies are designed to address complex challenges in cancer and cardiovascular disease research, facilitating advancements in precision medicine and non-invasive prenatal testing.

Logixboard, Inc. is a Seattle-based company founded in 2016 that offers a cloud platform designed to enhance transparency and communication for freight forwarders. The platform addresses inefficiencies in the $2 trillion freight forwarding industry, where many firms rely on outdated methods such as paper, spreadsheets, and email for tracking shipments. By integrating with existing back-office applications, Logixboard's solution serves as a digital customer engagement layer, enabling freight forwarders to streamline their operations and improve customer service. The platform empowers companies to manage and control their freight operations more effectively, ultimately reducing costs and increasing efficiency in a traditionally low-tech industry.

Sana Biotechnology is a biotechnology company focused on developing engineered cells as therapies for various diseases. Incorporated in 2018 and based in Seattle, Washington, with additional offices in South San Francisco and Cambridge, the company leverages recent scientific advancements to reprogram cells or replace damaged cells and tissues. Sana's mission is to create a new class of medicines that address unmet treatment needs across a wide range of therapeutic areas, including oncology, diabetes, autoimmune disorders, and central nervous system conditions. Its pipeline includes several product candidates, such as SC291, SC262, SC255, and UP421, aimed at transforming the approach to disease treatment.

NodThera Limited is a biotechnology company focused on researching and developing novel inhibitors of the NLRP3 inflammasome, which play a critical role in inflammatory and neuroinflammatory diseases. Established in 2016 and headquartered in Little Chesterford, United Kingdom, NodThera operates a laboratory in Seattle, Washington, and a corporate office in Lexington, Massachusetts. The company aims to create therapies targeting a range of conditions including arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers. By developing potent and selective NLRP3 inflammasome inhibitors, NodThera seeks to reduce pro-inflammatory cytokines, enabling more effective treatment options for patients suffering from chronic inflammation-related diseases.

Avalyn Pharma, Inc. is a biopharmaceutical company focused on developing therapies for idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company is advancing inhaled formulations of pirfenidone, specifically AP01, which aims to enhance drug delivery to the lungs while potentially reducing side effects associated with oral treatments. This innovative approach seeks to improve the care and outcomes for patients suffering from these conditions. Established in 2011, Avalyn Pharma operates from its headquarters in Seattle, Washington, and maintains an additional office in San Diego, California. The company was previously known as Genoa Pharmaceuticals, Inc. before rebranding in July 2017.

Logixboard, Inc. is a Seattle-based company founded in 2016 that offers a cloud platform designed to enhance transparency and communication for freight forwarders. The platform addresses inefficiencies in the $2 trillion freight forwarding industry, where many firms rely on outdated methods such as paper, spreadsheets, and email for tracking shipments. By integrating with existing back-office applications, Logixboard's solution serves as a digital customer engagement layer, enabling freight forwarders to streamline their operations and improve customer service. The platform empowers companies to manage and control their freight operations more effectively, ultimately reducing costs and increasing efficiency in a traditionally low-tech industry.

Sana Biotechnology is a biotechnology company focused on developing engineered cells as therapies for various diseases. Incorporated in 2018 and based in Seattle, Washington, with additional offices in South San Francisco and Cambridge, the company leverages recent scientific advancements to reprogram cells or replace damaged cells and tissues. Sana's mission is to create a new class of medicines that address unmet treatment needs across a wide range of therapeutic areas, including oncology, diabetes, autoimmune disorders, and central nervous system conditions. Its pipeline includes several product candidates, such as SC291, SC262, SC255, and UP421, aimed at transforming the approach to disease treatment.

Sana Biotechnology is a biotechnology company focused on developing engineered cells as therapies for various diseases. Incorporated in 2018 and based in Seattle, Washington, with additional offices in South San Francisco and Cambridge, the company leverages recent scientific advancements to reprogram cells or replace damaged cells and tissues. Sana's mission is to create a new class of medicines that address unmet treatment needs across a wide range of therapeutic areas, including oncology, diabetes, autoimmune disorders, and central nervous system conditions. Its pipeline includes several product candidates, such as SC291, SC262, SC255, and UP421, aimed at transforming the approach to disease treatment.

NodThera Limited is a biotechnology company focused on researching and developing novel inhibitors of the NLRP3 inflammasome, which play a critical role in inflammatory and neuroinflammatory diseases. Established in 2016 and headquartered in Little Chesterford, United Kingdom, NodThera operates a laboratory in Seattle, Washington, and a corporate office in Lexington, Massachusetts. The company aims to create therapies targeting a range of conditions including arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers. By developing potent and selective NLRP3 inflammasome inhibitors, NodThera seeks to reduce pro-inflammatory cytokines, enabling more effective treatment options for patients suffering from chronic inflammation-related diseases.

Avalyn Pharma, Inc. is a biopharmaceutical company focused on developing therapies for idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company is advancing inhaled formulations of pirfenidone, specifically AP01, which aims to enhance drug delivery to the lungs while potentially reducing side effects associated with oral treatments. This innovative approach seeks to improve the care and outcomes for patients suffering from these conditions. Established in 2011, Avalyn Pharma operates from its headquarters in Seattle, Washington, and maintains an additional office in San Diego, California. The company was previously known as Genoa Pharmaceuticals, Inc. before rebranding in July 2017.